Clinical Trial Overview
The Power of
PRAME Therapies
Immatics is the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. The Company’s robust clinical pipeline forms the broadest PRAME franchise with the most PRAME indications and modalities.
Featured Clinical Trial Enrolling Now
IMA203-301 (SUPRAME)
SUPRAME is a randomized Phase 3 clinical trial evaluating the efficacy, safety and tolerability of treatment with IMA203 versus investigator’s choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma.
Interested in learning more?
Store locator is loading from StoreRocket Store Locator App..
Additional Clinical Trials Enrolling Now
IMA203-101/IMA203CD8
This Phase 1 clinical trial is ongoing to evaluate the safety and tolerability of IMA203 or IMA203CD8 products in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Interested in learning more?
IMA402-101
This Phase 1/2 clinical trial is evaluating the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors.
Interested in learning more?
IMA401-101
This Phase 1a/b first-in-human clinical trial is evaluating the safety, tolerability and initial anti-tumor activity of IMA401 as a monotherapy or in combination with a checkpoint inhibitor in patients with recurrent and/or refractory solid tumors.
Interested in learning more?
Connect With Clinical Trial Opportunities
If you or someone you care for may be interested in an Immatics clinical trial, talk to your healthcare provider to explore potential eligibility.
For healthcare professionals, contact us to learn more about current trials and how to refer a patient.